Bibliographic Details
| Title: |
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual... |
| Authors: |
Tolaney, Sara M., DeMichele, Angela, Takano, Toshimi, Rugo, Hope S., Perou, Charles, Metzger, Otto, Parsons, Heather Anne, Santa-Maria, Cesar Augusto, Rocque, Gabrielle Betty, Yao, Wenliang, Sun, Shawn W., Mocci, Simonetta, Partridge, Ann H., Carey, Lisa A. |
| Source: |
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS619-TPS619, 1p |
| Database: |
Supplemental Index |
